Agarwal N et al. Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): A randomised, placebo-controlled, phase 3 trial. Lancet Oncol 2023;402(10398):291-303. Abstract
Chi KN et al. Safety analyses of the phase 3 VISION trial of [ 177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer. Eur Urol 2024;85(4):382-91. Abstract
Chi KN et al. Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial. Ann Oncol 2023;34(9):772-82. Abstract
Clarke N et al. Final overall survival (OS) in PROpel: Abiraterone (abi) and olaparib (ola) versus abiraterone and placebo (pbo) as first-line (1L) therapy for metastatic castration-resistant prostate cancer (mCRPC). Genitourinary Cancers Symposium 2023;Abstract LBA16.
Fizazi K et al. First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: The phase 3 TALAPRO-2 trial. Nature Med 2024;30(1):257-64. Abstract
Higano CS et al. Safety and effectiveness of the radium-223-taxane treatment sequence in patients with metastatic castration-resistant prostate cancer in a global observational study (REASSURE). Cancer 2024;[Online ahead of print]. Abstract
Rahbar K et al. 177Lu-prostate-specific membrane antigen therapy in patients with metastatic castration-resistant prostate cancer and prior 223Ra (RALU Study). J Nucl Med 2023;64(1):1925-31. Abstract
Saad F et al. Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): Final prespecified overall survival results of a randomised, double-blind, phase 3 trial. Lancet Oncol 2023;24(10):1094-108. Abstract
Sandhu S et al. LuPARP: Phase 1 trial of 177Lu-PSMA-617 and olaparib in patients with metastatic castration resistant prostate cancer (mCRPC). ASCO 2023;Abstract 5005.
Sandhu S et al. PRINCE: Phase I trial of 177Lu-PSMA-617 in combination with pembrolizumab in patients with metastatic castration-resistant prostate cancer (mCRPC). ASCO 2022;Abstract 5017.
Sartor O et al. Phase III trial of [177Lu]Lu-PSMA-617 in taxane-naïve patients with metastatic castration-resistant prostate cancer (PSMAfore). ESMO 2023;Abstract LBA13.
Sartor O et al. Lutetium- 177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med 2021;385(12):1091-103. Abstract
Shore N et al. EMBARK: A phase 3 randomized study of enzalutamide or placebo plus leuprolide acetate and enzalutamide monotherapy in high-risk biochemically recurrent prostate cancer. AUA 2023;Abstract LBA02-09.
Song DY et al. Real-world safety and effectiveness of radium-223 (223Ra) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated in the US: The non-interventional REASSURE study. ASCO 2023;Abstract 5050.